Results 31 to 40 of about 396 (132)

Long‐acting growth hormone in 2022

Pediatric Investigation, Volume 7, Issue 1, Page 36-42, March 2023., 2023
After successful clinical use of growth hormone (GH) for nearly 70 years, we are now able to use long‐acting GH (LAGH) with identical or even slightly greater efficacy in clinical medicine in GH deficiency in children and adults. ABSTRACT After the isolation of pituitary growth hormone (GH) in 1957, this form of GH, always in limited supply, was the ...
Margaret Steiner, Jacklyn Frank, Paul Saenger   +2 more
wiley   +1 more source

Annual banned‐substance review—Analytical approaches in human sports drug testing 2021/2022–

Drug Testing and Analysis, Volume 15, Issue 1, Page 5-26, January 2023., 2023
Detection assays for drugs and methods of sports doping published between 2021 and 2022 are critically reviewed and evaluated in context with the Prohibited List 2022 as established by the World Anti‐Doping Agency. Abstract Also in 2021/2022, considerable efforts were invested into advancing human sports drug testing programs, recognizing and taking ...
Mario Thevis, Tiia Kuuranne, Hans Geyer
wiley   +1 more source

Model-based somapacitan dosing and IGF-I response in children born SGA or with ISS, Noonan or Turner syndromes. [PDF]

J Endocr Soc
Abstract Context The weekly insulin-like growth factor I (IGF-I) profile for children and adolescents treated with long-acting growth hormone differs from that of daily growth hormone (GH). Objective The objective of ...
Desrochers J, Backeljauw P, Højby M, Juul Kildemoes R, Linglart A, Mori J, Leisegang RF.   +6 more
europepmc   +4 more sources

Growth Response to Weekly Somapacitan Therapy in Children With GH Deficiency Is Related to GH Thresholds in GH Stimulation Testing. [PDF]

J Endocr Soc
Context The lack of a severity definition and standardized GH cutoff level for GH deficiency (GHD) diagnosis in children leads to ambiguity in the interpretation of GH stimulation tests and treatment recommendations.Objective To investigate treatment ...
Backeljauw PF, Boettcher C, Højby M, Kelepouris N, Jeppesen ML, Mori J, Pietropoli A, Miller BS.   +7 more
europepmc   +2 more sources

Supplementary appendix for "Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety and Treatment/Disease Burden Results from REAL 3"

, 2023
Supplementary appendix for "Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety and Treatment/Disease Burden Results from REAL 3"
Lars Sävendahl (9986312), Reiko Horikawa (393659), Meryl Brod (11257694), Michael Højby Rasmussen (14699299), Tadej Battelino (4256770), Paul Saenger (14716153), Sebastian Röhrich (370448)   +6 more
core   +1 more source

Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials [PDF]

Clinical Pharmacokinetics, 2021
Somapacitan is a long-acting growth hormone (GH) derivative being developed for once-weekly dosing in patients with GH deficiency (GHD). Our objective was to evaluate the impact of kidney or hepatic impairment on somapacitan exposure in adults.In two open-label, parallel-group, single-center, 6-week trials, eligible subjects (18-75 years of age, body ...
Birgitte Bentz Damholt, Sarah Louise Dombernowsky, Mette Dahl Bendtsen, Charlotte Bisgaard, Michael Højby Rasmussen   +4 more
openaire   +2 more sources

Plain language summary for "Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety and Treatment/Disease Burden Results from REAL 3"

, 2023
Plain language summary for "Childhood growth hormone deficiency, growth hormone treatment, daily growth hormone, somapacitan, long-acting growth hormone"
Lars Sävendahl (9986312), Reiko Horikawa (393659), Meryl Brod (11257694), Michael Højby Rasmussen (14699299), Tadej Battelino (4256770), Paul Saenger (14716153), Sebastian Röhrich (370448)   +6 more
core   +1 more source

Supplementary Material for "Model-based analysis of IGF-I response, dosing, and monitoring for once-weekly somapacitan in children with GH deficiency"

, 2023
Supplementary Material for "Model-based analysis of IGF-I response, dosing, and monitoring for once-weekly somapacitan in children with GH deficiency"
Philippe Backeljauw (11705857), Joanne Blair (9991035), Rasmus Juul Kildemoes (9468638), Michael Højby Rasmussen (14699299), Jun Mori (16881669), Yassine Kamal Lyauk (16881086), Bradley Miller (9991046)   +6 more
core   +1 more source

Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan [PDF]

The Journal of Clinical Endocrinology & Metabolism, 2020
Abstract Context Somapacitan is a long-acting growth hormone (GH) in development for once-weekly treatment of GH deficiency (GHD). Optimal monitoring of insulin-like growth factor-I (IGF-I) levels must account for weekly IGF-I fluctuations following somapacitan administration.
Rasmus Juul Kildemoes, Michael Højby Rasmussen, Henrik Agersø, Rune Viig Overgaard   +3 more
openaire   +2 more sources

Efficacy and Safety of Somapacitan versus Daily Growth Hormone in Children with Growth Hormone Deficiency: A Pooled Analysis of Randomised Trial Data.

Horm Res Paediatr
Sävendahl L, Maniatis AK, Pietropoli A, Kelepouris N, Højby M, Ferran JM, Fu J, Mori J, Wabitsch M, Miller BS.   +9 more
europepmc   +2 more sources